Interventions to reduce platelet prophylactic transfusions in patients with hypoproliferative thrombocytopenia: Providing patients with the full benefit

Clinical Laboratory

Volumn 59, Issue 5-6, 2013, Pages 459-464

  Vamvakas, Eleftherios C ^b   Hitzler, Walter E ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APHERESIS; BLEEDING; DONOR; HUMAN; HYPOPROLIFERATIVE THROMBOCYTOPENIA; PROPHYLAXIS; RISK REDUCTION; SHORT SURVEY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

DISEASE TRANSMISSION, INFECTIOUS; HEALTH POLICY; HEMORRHAGE; HUMANS; PATIENT SAFETY; PLATELET COUNT; PLATELET TRANSFUSION; PLATELETPHERESIS; THROMBOCYTOPENIA;

EID: 84879360481     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.130307     Document Type: Short Survey

References (15)

1. Vamvakas EC, Blajchman MA. Blood still kills: Six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124.
2. Vamvakas EC. Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: A systematic review of disparate risks. Transfusion 2009;49:2743-58.
3. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Transfusion 2012; DOI 10.1111/j.1537-2995.2012.03825.x
4. Vamvakas EC, Hitzler WE. Consistency and proportionality in policy decision-making in blood safety: The case for an all-apheresis platelet supply in Germany. Clin Lab 2013;59:1-22.
5. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with hematological malignancies: Where to now? Br J Haematol 2005;131:588-95. (Pubitemid 43903803)
6. Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with hematological disorders after chemotherapy and stem-cell transplantation. Cochrane Datab System Rev 2012:CD004259.
7. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997;337:1870-5.
8. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with hematological malignancies: an open-label, multicenter, randomized study. Lancet 2012;380:1309-16.
9. Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (Trial of Platelet Prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010;24:163-71.
10. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2012;362:600-13.
11. Department of Health and Human Services. The 2007 National Blood Collection and Utilization Survey Report. Washington, DC:DHHS, 2008.
12. Department of Health and Human Services. The 2009 National Blood Collection and Utilization Survey Report. Washington, DC: DHHS, 2011.
13. st century - an acquired human prion disease with very long incubation periods. Lancet 2006;367:2068-74.
14. Vamvakas EC. Establishing causation in transfusion medicine and related tribulations. Transfus Med Rev 2011;25:81-8.
15. th meeting of the Spongiform Encephalopathy Advisory Committee, London, United Kingdom, March 5, 2010. Available at: http://webarchive.nationalarchives.gov.uk/20110316162957/http:/ www.seac.gov.uk/minutes/minutes104.pdf [AccessedMar5 2013].